199 related articles for article (PubMed ID: 19149228)
1. Prostate disease prevalence with epidemiological and hormonal analysis in randomly selected male population in Croatia.
Galić J; Simunović D
Coll Antropol; 2008 Dec; 32(4):1195-202. PubMed ID: 19149228
[TBL] [Abstract][Full Text] [Related]
2. [Who works in the prevention and early detection of benign prostatic hyperplasia and prostate cancer in Croatia?].
Kranjcević K; Marković BB
Acta Med Croatica; 2007 Feb; 61(1):45-8. PubMed ID: 17593640
[TBL] [Abstract][Full Text] [Related]
3. Benign prostatic hyperplasia, prostate cancer and other prostate diseases diagnosed as a result of screening procedure among 1,004 men in the Lublin district.
Opalińska E; Stoma F; Michalak A; Latalski M; Goniewicz M
Ann Univ Mariae Curie Sklodowska Med; 2002; 57(1):493-501. PubMed ID: 12898966
[TBL] [Abstract][Full Text] [Related]
4. Risk factors for lower urinary tract symptoms suggestive of benign prostatic hyperplasia in a community based population of healthy aging men: the Krimpen Study.
Kok ET; Schouten BW; Bohnen AM; Groeneveld FP; Thomas S; Bosch JL
J Urol; 2009 Feb; 181(2):710-6. PubMed ID: 19091352
[TBL] [Abstract][Full Text] [Related]
5. Is prostate cancer screening justified in the Bedouin population?
Abdallah M; Lazarev I; Ariad S; Mermershtain W
Onkologie; 2009 May; 32(5):260-2. PubMed ID: 19420972
[TBL] [Abstract][Full Text] [Related]
6. Prostate growth and prevalence of prostate diseases in early onset spinal cord injuries.
Bartoletti R; Gavazzi A; Cai T; Mondaini N; Morelli A; Del Popolo G; Geppetti P
Eur Urol; 2009 Jul; 56(1):142-8. PubMed ID: 18280636
[TBL] [Abstract][Full Text] [Related]
7. Antibody array profiling reveals serum TSP-1 as a marker to distinguish benign from malignant prostatic disease.
Shafer MW; Mangold L; Partin AW; Haab BB
Prostate; 2007 Feb; 67(3):255-67. PubMed ID: 17192876
[TBL] [Abstract][Full Text] [Related]
8. The prevalence of erectile dysfunction among Brazilian men screened for prostate cancer.
Paranhos M; Antunes A; Andrade E; Freire G; Srougi M
BJU Int; 2009 Oct; 104(8):1130-3. PubMed ID: 19426190
[TBL] [Abstract][Full Text] [Related]
9. Case-control prostate cancer screening studies should not exclude subjects with lower urinary tract symptoms.
Godley PA; Carpenter WR
J Clin Epidemiol; 2007 Feb; 60(2):176-80. PubMed ID: 17208124
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of plasma interleukin-8 concentration in patients with prostate cancer and benign prostate hyperplasia.
Dehghani M; Mostafavi-Pour Z; Lotfi M; Shakeri S
Iran J Immunol; 2009 Jun; 6(2):92-8. PubMed ID: 19561378
[TBL] [Abstract][Full Text] [Related]
11. Testosterone levels in benign prostatic hypertrophy and prostate cancer.
Mearini L; Costantini E; Zucchi A; Mearini E; Bini V; Cottini E; Porena M
Urol Int; 2008; 80(2):134-40. PubMed ID: 18362481
[TBL] [Abstract][Full Text] [Related]
12. Genital and urinary tract diseases and prostate cancer risk.
Pelucchi C; Talamini R; Negri E; Franceschi S; La Vecchia C
Eur J Cancer Prev; 2006 Jun; 15(3):254-7. PubMed ID: 16679869
[TBL] [Abstract][Full Text] [Related]
13. Whole blood selenium levels (WBSL) in patients with prostate cancer (PC), benign prostatic hyperplasia (BPH) and healthy male inhabitants (HMI) and prostatic tissue selenium levels (PTSL) in patients with PC and BPH.
Muecke R; Klotz T; Giedl J; Buentzel J; Kundt G; Kisters K; Prott FJ; Micke O
Acta Oncol; 2009; 48(3):452-6. PubMed ID: 18855158
[TBL] [Abstract][Full Text] [Related]
14. Tissue and serum levels of principal androgens in benign prostatic hyperplasia and prostate cancer.
Heracek J; Hampl R; Hill M; Starka L; Sachova J; Kuncova J; Eis V; Urban M; Mandys V
Steroids; 2007 Apr; 72(4):375-80. PubMed ID: 17368496
[TBL] [Abstract][Full Text] [Related]
15. Serum resistin levels in benign prostate hyperplasia and non-metastatic prostate cancer: possible role in cancer progression.
Housa D; Vernerova Z; Heracek J; Cechak P; Rosova B; Kuncova J; Haluzik M
Neoplasma; 2008; 55(5):442-6. PubMed ID: 18665756
[TBL] [Abstract][Full Text] [Related]
16. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: an autopsy study.
Stamatiou K; Alevizos A; Agapitos E; Sofras F
Prostate; 2006 Sep; 66(12):1319-28. PubMed ID: 16688747
[TBL] [Abstract][Full Text] [Related]
17. [Mass screening of prostate in Shiribeshi area in Hokkaido--incidence and clinical symptoms of benign prostatic hypertrophy and prostatic carcinoma].
Umehara T; Kumamoto Y; Mikuma N; Yamaguchi Y; Tsukamoto T; Miura T; Watanabe H; Ooe H
Hinyokika Kiyo; 1990 Apr; 36(4):415-23. PubMed ID: 1696062
[TBL] [Abstract][Full Text] [Related]
18. A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits.
Montorsi F; Alcaraz A; Desgrandchamps F; Hammerer P; Schröder F; Castro R
Prostate; 2009 Jun; 69(8):895-907. PubMed ID: 19267353
[TBL] [Abstract][Full Text] [Related]
19. Reliability of self-report versus chart-based prostate cancer, PSA, DRE and urinary symptoms.
Sayre EC; Bunting PS; Kopec JA
Can J Urol; 2009 Feb; 16(1):4463-71. PubMed ID: 19222884
[TBL] [Abstract][Full Text] [Related]
20. [Prostate-specific antigen--the most important cancer marker. Diagnostics and follow up of prostatic cancer have changed].
Bratt O; Björk T
Lakartidningen; 2007 Nov 14-20; 104(46):3460-4. PubMed ID: 18072615
[No Abstract] [Full Text] [Related]
[Next] [New Search]
